<DOC>
	<DOCNO>NCT00827112</DOCNO>
	<brief_summary>This pilot study examine novel treatment regimen maraviroc plus boosted atazanavir expect safe efficacious treatment naive HIV infect patient . Based result study , confirmatory phase 3 study may conduct .</brief_summary>
	<brief_title>A Pilot Study Of A Novel Treatment Regimen , Maraviroc + Ritonavir Boosted Atazanavir , In Treatment Naive HIV-Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>HIV1 RNA viral load ≥1,000 copies/mL measure Screening Visit . CD4 count ≥100 cells/mm3 Screening . Have R5 HIV1 Screening verify Monogram Bioscience Trofile® assay enhanced sensitivity . Prior treatment HIV antiretroviral therapy 14 day time . Any evidence resistance atazanavir , tenofovir , emtricitabine . X4or dual/mixedtropic virus enhance Trofile assay repeat assay failure reportable result .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>CCR5-tropic HIV-1 virus</keyword>
</DOC>